Figure 3.

Evolution of CD19+ B-cell counts during the follow-up periods. For most (75%) patients treated with rituximab, CD19+ B-cell depletion occurred rapidly within 1 week after the first infusion of rituximab.

Evolution of CD19+ B-cell counts during the follow-up periods. For most (75%) patients treated with rituximab, CD19+ B-cell depletion occurred rapidly within 1 week after the first infusion of rituximab.